Send to:

Choose Destination
See comment in PubMed Commons below
Praxis (Bern 1994). 2013 May 22;102(11):667-70. doi: 10.1024/1661-8157/a001293.

[Melanoma- finally good news].

[Article in German]

Author information

  • 1Departement Biomedizin, Universitätsspital und Universität Basel.


in English, French, German

Until two years ago, there was no systemic therapy that prolonged overall survival in patients with malignant melanoma. In the meantime, two new therapeutic approaches have improved the prognosis of this disease. Ipilimumab is an activator of cytotoxic T-cells. It induces an immune response which results in prolonged remission in 15-20% of patients. Vemurafenib is a specific BRAF inhibitor and induces quick and sometimes complete remissions in patients with BRAF V600E mutated melanomas. Thus, there are two new treatments with proven survival benefit in patients with metastatic melanoma.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for
    Loading ...
    Write to the Help Desk